HUMDF (Hua Medicine) Inventories, Work In Process: $3.74 Mil (As of Dec. 2025)


HUMDF Hua Medicine HUMDF
46 GF Score
Price $0.34
GF Value $1.46
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Hua Medicine Inventories, Work In Process?

Hua Medicine HUMDF 46 Inventories, Work In Process is $3.74 Mil as of Dec. 2025. GuruFocus rates HUMDF with a GF Score™ of 46/100 and a GF Value™ of $1.46 (Possible Value Trap). The stock has 6 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Hua Medicine's work in process for the quarter that ended in Dec. 2025 was $3.74 Mil.

Hua Medicine Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Hua Medicine's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hua Medicine Inventories, Work In Process Chart

Hua Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.05 0.12 0.07 3.74

Hua Medicine Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.00 0.07 0.00 3.74
HUMDF
46GF Score
Hua Medicine HUMDF
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hua Medicine Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $3.74 Mil mean?
Hua Medicine (HUMDF) has a Inventories, Work In Process of $3.74 Mil as of Dec. 2025. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Hua Medicine and its competitors.
Is Hua Medicine's Inventories, Work In Process too high?
Hua Medicine's current Inventories, Work In Process is $3.74 Mil. Overall, Hua Medicine has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's Inventories, Work In Process compare to ZTS and UTHR?
Hua Medicine's Inventories, Work In Process of $3.74 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Drug Manufacturers company?
A good Inventories, Work In Process depends on the Drug Manufacturers industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Hua Medicine and its competitors. Hua Medicine's current Inventories, Work In Process is $3.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.46, compared to a current price of $0.34 — trading 76.7% below its estimated fair value. The current Inventories, Work In Process is $3.74 Mil. Hua Medicine's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current Inventories, Work In Process is $3.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hua Medicine (HUMDF) Overvalued in 2026?

Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued. The current stock price of $0.34 is trading 76.7% below its estimated GF Value™ of $1.46. GuruFocus considers Hua Medicine to be Possible Value Trap.

Key valuation signals for HUMDF:

  • Inventories, Work In Process: $3.74 Mil
  • GF Value™: $1.46 vs. price of $0.34 (76.7% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hua Medicine Business Description

Other Exchanges 02552:Hong Kong
Address Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score

Get the complete analysis for HUMDF

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price
$1.46
GF Value